I-tech: BPC considers Medetomidine ED - ABG

ECHA's BPC adopts opinion that Medetomidine has ED properties
European Commission now to decide on potential exception
We believe case for exception good, EU only 10% of market


ECHA BPC opines that Medetomidine has ED properties

I-Tech announced today in a press release, that the European Chemicals Agency (ECHA) Biocidal Products Committee (BPC) has adopted an opinion that Medetomidine, the active substance in Selektope, has endocrine disrupting (ED) properties. This means that the BPC chose to agree with the opinion of the ED expert panel that was announced a year ago. The renewal process now moves on to the next stage, in which the European Commission will decide whether renewal can be justified anyway, based on socio-economic considerations. Active substances that are identified as having endocrine disrupting properties can only be approved under certain specific circumstances outlined under Article 5(2) of the BPR, relating to negligible exposure, essential use, or whether non-approval would result in a disproportionate negative impact on society. The availability of suitable and sufficient alternative substances or technologies is also a key consideration, and Selektope is one of only three substances on the global market that address barnacle fouling and hard fouling.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/i-tech/Equity-research/2024/6/i-tech---bpc-considers-medetomidine-ed/